Equities
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)370.00
  • Today's Change18.00 / 5.11%
  • Shares traded218.67k
  • 1 Year change+7.40%
  • Beta2.1631
Data delayed at least 20 minutes, as of Jul 14 2025 16:35 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Oxford Biomedica PLC is a contract development and manufacturing organization (CDMO) in cell and gene therapy. The Company is engaged in providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. It offers a number of technologies for viral vector manufacturing, including a fourth-generation lentiviral vector system (the TetraVecta system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. Its LentiVector platform technology is an advanced lentiviral vector-based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. Its AAV platform, which offers a proprietary plug and play dual-plasmid system for transient transfection, as well as a standard triple transfection system for AAV-based gene therapies.

  • Revenue in GBP (TTM)128.80m
  • Net income in GBP-43.19m
  • Incorporated1996
  • Employees861.00
  • Location
    OXBWindrush Court, Transport WayOXFORD OX4 6LTUnited KingdomGBR
  • Phone+44 186 578 3000
  • Fax+44 186 578 3001
  • Websitehttps://www.oxb.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Scancell Holdings Plc0.00-15.81m106.27m61.00---------0.0171-0.01710.00-0.0150.00----0.00-81.40-31.66-625.06-37.66-------822.37---42.23251.00---100.00--50.91--131.54--
Avacta Group Plc11.26m-29.43m123.80m151.00--12.74--10.99-0.085-0.14960.03270.02510.18540.002.6474,576.16-48.46-43.48-172.33-78.2744.5963.54-261.32-781.441.08-0.57120.7229---96.04---0.9503------
Bioventix PLC13.66m7.85m144.99m17.0018.7412.8418.2310.611.481.482.582.161.042.172.21803,738.3059.9858.3369.0663.6290.9593.0957.4264.126.69--0.0090.926.177.93-3.296.67-28.4016.25
4Basebio PLC933.00k-12.33m155.09m----5.87--166.23-0.9391-0.93910.07111.700.03290.85844.78---43.54-36.81-48.26-40.9867.5269.88-1,321.87-1,160.8311.18-19.680.3658--84.3935.80-60.90--50.57--
Faron Pharmaceuticals Oy0.00-22.44m233.36m25.00---------0.2682-0.26820.00-0.08080.00----0.00-227.96-227.46---1,738.54-----------2.585.15------16.24--17.71--
Puretech Health PLC3.58m39.64m315.10m56.007.421.0213.5788.100.17640.17640.0141.280.0075--2.4863,867.544.29-3.274.57-3.83----575.43-253.25----0.052--44.98-13.21181.45-33.81-75.53--
Oxford BioMedica plc128.80m-43.19m373.60m861.00--6.54--2.90-0.414-0.4141.240.53840.53225.734.71149,590.00-20.09-20.23-25.99-25.4841.1749.36-37.74-45.032.05-5.420.6426--43.8414.9972.58---21.89--
Allergy Therapeutics plc55.66m-35.65m393.23m602.00------7.07-0.0075-0.00750.0117-0.00150.78362.156.0092,453.49-50.19-22.88-78.92-30.1554.0466.47-64.05-24.881.15-4.071.19---7.36-5.626.63--1.88--
Genus plc671.60m-4.00m1.47bn3.44k--2.8437.212.18-0.0612-0.061210.167.820.6585--6.11195,289.30-0.62753.30-0.71993.87-----0.9534.981.33--0.365662.72-3.036.48-76.280.2551-2.682.93
Data as of Jul 14 2025. Currency figures normalised to OXB's reporting currency: UK Pound GBX

Institutional shareholders

49.99%Per cent of shares held by top holders
HolderShares% Held
Briarwood Chase Management LLCas of 09 Jun 202513.85m13.07%
Vulpes Investment Management Pte Ltd.as of 21 Mar 20258.45m7.97%
M&G Investment Management Ltd.as of 21 Mar 20255.87m5.54%
Liontrust Investment Partners LLPas of 29 Oct 20245.27m4.97%
Threadneedle Asset Management Ltd.as of 21 Mar 20253.83m3.62%
Barclays Bank Plc (Private Banking)as of 01 Jun 20253.78m3.57%
BlackRock Investment Management (UK) Ltd.as of 01 Oct 20243.64m3.44%
Hargreaves Lansdown Asset Management Ltd.as of 21 Mar 20253.48m3.28%
Charles Schwab Investment Management, Inc.as of 01 Jun 20252.73m2.58%
Banque Pictet & Cie SAas of 01 Jun 20252.07m1.96%
More ▼
Data from 31 Mar 2025 - 01 Jul 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.